534-535 / 1708
NICE Committee Concludes….........
•
‘the dinutuximab regimen appears to confer a small event-free
survival advantage and overall survival advantage compared with
isotretinoin…’
•
‘2.81 life years (approximately 33.7 months) were gained for the
dinutuximab regimen compared with isotretinoin alone’
•
i.e. patients could expect to live for nearly 3 years longer if treated
with anti-GD2-based immunotherapy rather than retinoic acid
maintenance alone.
•
‘dinutuximab does not represent a cost-effective use of NHS
resources…’